Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
1.380
+0.045 (3.37%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.
Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Enveric Biosciences, Inc.
| Country | United States |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Joseph Tucker |
Contact Details
Address: 4851 Tamiami Trail N, Suite 200 Naples, Florida 34103 United States | |
| Phone | 239 302 1707 |
| Website | enveric.com |
Stock Details
| Ticker Symbol | ENVB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000890821 |
| CUSIP Number | 29405E208 |
| ISIN Number | US29405E2081 |
| Employer ID | 95-4484725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | Chief Executive Officer and Director |
| Kevin M. Coveney C.P.A. | Chief Financial Officer |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | EFFECT | Notice of Effectiveness |
| Apr 16, 2025 | ARS | Filing |
| Apr 15, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 10, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 4, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2025 | SCHEDULE 13G/A | Filing |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 10-K | Annual Report |